- Home
- TRML
TRML
Tourmaline Bio Inc.
as 07-26-2024 4:00pm EST
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 382.4M | IPO Year: | N/A |
| Target Price: | $61.80 | AVG Volume (30 days): | 344.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.18 - $48.31 | Next Earning Date: | 08-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tourmaline Bio Inc. (TRML)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MCDADE MARK | TRML | Director | Jan 29 '24 | Buy | $32.50 | 100,000 | $3,250,000.00 | 448,431 | SEC Form 4 |
| Kulkarni Sandeep Chidambar | TRML | CEO | Nov 17 '23 | Buy | $16.99 | 4,000 | $67,960.00 | 729,735 | SEC Form 4 |
| Thiara Parvinder | TRML | Director | Nov 17 '23 | Buy | $17.31 | 1,000 | $17,310.00 | 83,782 | SEC Form 4 |
| KANTOFF AARON | TRML | Director | Oct 24 '23 | Buy | $11.86 | 7,500 | $88,950.00 | 45,391 | SEC Form 4 |
| Thiara Parvinder | TRML | Director | Oct 24 '23 | Buy | $10.66 | 5,000 | $53,300.00 | 80,782 | SEC Form 4 |
| Thiara Parvinder | TRML | Director | Oct 24 '23 | Buy | $12.12 | 2,000 | $24,240.00 | 82,782 | SEC Form 4 |
Latest Tourmaline Bio Inc. News
TRML Breaking Stock News: Dive into TRML Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
GlobeNewswire
2 months ago
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
2 months ago
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
GlobeNewswire
2 months ago
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
4 months ago
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
GlobeNewswire
4 months ago
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Simply Wall St.
5 months ago
Bullish Tourmaline Bio Insiders Loaded Up On US$643.3k Of Stock
GlobeNewswire
5 months ago
Tourmaline Bio to Present at Upcoming Investor Conferences
Compare TRML vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRML Tourmaline Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.